7:00 a.m. – 8:00 a.m.

Sign-in Room: Palm BC

8:00 a.m. – 8:05 a.m.

Opening of Steering Committee Meeting and Approval of February 21st, 2024 EDRN Steering Committee Meeting Minutes

• Arul Chinnaiyan MD, University of Michigan
• Karen Anderson, MD, PhD, Arizona State University

8:05 a.m. – 8:10 a.m.

Welcome

• Sally C. Morton, PhD, Executive Vice President, Arizona State University

8:10 a.m. – 8:30 a.m.

8:30 a.m. - 8:40 a.m. Q&A

State of the EDRN

• 01: Sudhir Srivastava, PhD, MPH, Chief, Program Officer | Cancer Biomarkers National Cancer Institute

8:40 a.m. – 12:20 p.m.

Biomarker Reference Laboratories

8:40 a.m. – 8:55 a.m.

8:55 a.m. – 9:00 a.m. Q&A

Breast

• 02: University of Washington, Andrew Hoofnagle, MD, PhD
• Fred Hutchinson Cancer Center, Amanda Paulovich, MD, PhD

9:00 a.m. – 9:15 a.m.

9:15 a.m. – 9:20 a.m. Q&A

Colon and Esophagus

• 03: Fred Hutchinson Cancer Center, Cecilia Yeung, MD
• Fred Hutchinson Cancer Center, William Grady, MD

9:20 a.m. – 9:35 a.m.

9:35 a.m. – 9:40 a.m. Q&A

Prostate

• 04: Eastern Virginia Medical School, O. John Semmes, PhD
• University of California, Los Angeles, Paul Boutros, PhD
• University of Toronto, Thomas Kislinger, PhD

9:40 a.m. – 9:55 a.m.

9:55 a.m. – 10:00 a.m. Q&A

Lung

• 05: LungLife AI, Inc., Paul Pagano, PhD
• Boston University, Marc Lenburg, PhD
• Veracyte Inc., Giulia Kennedy, PhD
• University of California, Los Angeles, Michael Palazzolo, MD, PhD

10:00 a.m. – 10:20 a.m.

Break

10:20 a.m. – 10:35 a.m.

10:35 a.m. – 10:40 a.m. Q&A

Lung

• 06: New York University Grossman School of Medicine, Leopoldo Segal MD
• New York University School of Medicine, Harvey Pass, MD

10:40 a.m. – 10:55 a.m.

10:55 a.m. – 11:00 a.m. Q&A

Lung and Ovary

• 07: Meso Scale Diagnostics, Anu Mathew, PhD
• Arizona State University, Joshua LaBaer, MD, PhD
• Meso Scale Diagnostics, Martin Stengelin, PhD

11:00 a.m. – 11:15 a.m.

11:15 a.m. – 11:20 a.m. Q&A

Ovary

• 08: Massachusetts General Hospital, Steven Skates, PhD
• University Health Network, Vathany Kulasingam, PhD

11:20 a.m. – 11:35 a.m.

11:35 a.m. – 11:40 a.m. Q&A

Prostate and Ovary

• 09: Johns Hopkins Medical Institutions, Daniel Chan, PhD
• Johns Hopkins University, Zhen Zhang, PhD

11:40 a.m. – 11:55 a.m.

11:55 a.m. – 12:00 p.m. Q&A

Prostate

• 10: Vanderbilt University Medical Center, Jeffrey Tosoian, MD
• University of Michigan, Arul Chinnaiyan, MD, PhD
• LynxDx, John Kitchen, PhD
• University of Michigan, Lanbo Xiao, PhD

12:00 p.m. – 12:15p.m.

12:15 p.m. – 12:20 p.m. Q&A

Lung

• 11: University of Pittsburgh School of Medicine, James Herman MD
• University of Maryland School of Medicine, Sanford Stass, MD

12:20 p.m. – 2:00 p.m.

Lunch (On Your Own)

12:20 p.m. – 2:00 p.m.

Executive Committee Meeting (closed)
Room: Palm F

2:00 p.m. – 6:00 p.m.

Collaborative Group Meetings

• Breast and Gynecologic Cancers Gynecologic
  Room: Palm E
• Gastrointestinal and Associated Cancers
  Room: Joshua Tree
• Lung and Upper Aerodigestive Cancers & Head and Neck
  Room: Palm BC
• Prostate and Urologic Cancers
  Room: Xavier

6:00 p.m.

Adjourn for the Day

7:00 a.m. – 8:00 a.m.

Sign-in
Room: Palm B & C

8:00 a.m. – 9:20 a.m.

Navigating Statistical Challenges in Early Detection Trial Design for Single-organ and Multi-Cancer Early Detection (MCED)

8:00 a.m.- 8:20 a.m.

Which sensitivity matters most in population screening studies?

• 01: Ruth Etzioni, PhD, Fred Hutchinson Cancer Center

8:20 a.m.– 8:40 a.m.

Raising the bar for launching screening trials – Which criteria should be satisfied?

• 02: Yingye Zheng, PhD, Fred Hutchinson Cancer Center

8:40 a.m. – 9:00 a.m.

What can we learn from prior cancer screening trials about stage and mortality endpoints?

• 03: Hilary Robbins PhD, International Agency for Research on Cancer (IARC) - (virtual)

9:00 a.m. – 9:20 a.m.

Q&A

9:20 a.m. – 12:10 p.m.

Collaborative Group Updates and Vision/Strategic Plan for EDRN Research

9:20 a.m. – 9:45 a.m.

9:45 a.m. – 9:55 a.m. Q&A

Breast and Gynecological Cancers

• 04: Chair: Chris Li, MD, PhD, Fred Hutchinson Cancer Center
• Co-chair: Steven Skates, PhD, Massachusetts General Hospital

9:55 a.m. – 10:25 a.m.

Break

10:25 a.m. –10:50 a.m.

10:50 a.m. –11:00 a.m. Q&A

Lung and Upper Aerodigestive Cancers

• 05: Chair: Marc Lenburg, PhD, Boston University
• Co-chair: Eric Grogan, MD, Vanderbilt University Medical Center

11:00 a.m. – 11:25 a.m.

11:25 a.m. – 11:35 a.m. Q&A

Prostate and Urologic Cancers

• 06: Chair: O. John Semmes, PhD, Eastern Virginia Medical School
• Co-chair: Jeff Tosoian, MD, Vanderbilt University Medical Center

11:35 a.m. – 12:00 p.m.

12:00 p.m. – 12:10 p.m. Q&A

Gastrointestinal and Associated Cancers

• 07: Chair: Amitabh Chak, MD, UH Cleveland Medical Center,
• Co-chair: Cecilia Yeung, MD, Fred Hutchinson Cancer Center

12:10 p.m. – 1:30 p.m.

Lunch (On Your Own)

1:30 p.m. – 3:00 p.m.

Round Table Discussions Based on Methodological Approaches

Topics based on suggestions from Collaborative Groups

#1 Imaging, Biomarkers & Radiomics
Room: Palm E

• Eric Grogan, MD, Vanderbilt -Ingram Cancer Center
• Matthew Schabath, PhD, H. Lee Moffitt Cancer Center & Research Institute, Inc.
• Guillermo Marquez, PhD, National Cancer Institute

#2 Digital Pathology – AI and ML
Room: Joshua Tree

• Anirban Maitra, MBBS, The University of Texas M.D. Anderson Cancer Center
• Andrew Hoofnagle, MD, PhD, University of Washington
• Sidney Fu, MD, National Cancer Institute

#3 Spatial-Omics
Room: Xavier

• Cecilia Yeung, MD, Fred Hutchinson Cancer Center
• O. John Semmes, PhD, Eastern Virginia Medical School
• Indu Kohaar PhD, National Cancer Institute

#4 Cell Free DNA
Room: Palm F

• Cristian Tomasetti, PhD, City of Hope/Tgen
• Joshua LaBaer, MD, PhD, Arizona State University
• Christos Patriotis PhD, National Cancer Institute

3:00 p.m. – 3:20 p.m.

Break

3:20 p.m. – 5:00 p.m.

Other NCI Programs
Room: Palm BC

3:20 p.m. – 3:35 p.m.

3:35 p.m. – 3:40 p.m. Q&A

NCI Center for Global Health Support for Global Health Technology Research

08: Paul Pearlman, PhD, National Cancer Institute

3:40 p.m. – 3:55 p.m.

3:55 p.m. – 4:00 p.m. Q&A

Assay Validation of High Quality Markers for Clinical Studies in Cancer

09: Sumana Dey, PhD, National Cancer Institute

4:00 p.m. – 4:15 p.m.

4:15 p.m. – 4:20 p.m. Q&A

Cancer Prevention Clinical Trials Network (CP-CTNet)

10: Eva Szabo, MD, National Cancer Institute

4:20 p.m. – 4:35 p.m.

4:35 p.m. – 4:40 p.m. Q&A

Cancer Prevention-Interception Targeted Agent Discovery Program CAP-IT

11: Shizuko Sei, MD, National Cancer Institute

4:40 p.m. – 4:55 p.m.

4:55 p.m. – 5:00 p.m. Q&A

PREVENT Program Agent Development Pipeline

12: Mark Miller, PhD, National Cancer Institute

5:00 p.m. – 6:30 p.m.

Development of Trans-EDRN BRL Projects

6:30 p.m.

Adjourn for the Day

7:00 a.m. – 8:00 a.m.

Sign-in Room: Palm B & C

8:00 a.m. – 10:00 a.m.

Reports from Round Table Discussions

Four 30-minute talks

#1 Imaging, Biomarkers & Radiomics

• 01: Eric Grogan, MD, Vanderbilt -Ingram Cancer Center
• Matthew Schabath, PhD, H. Lee Moffitt Cancer Center & Research Institute, Inc.
• Guillermo Marquez, PhD, National Cancer Institute

#2 Digital Pathology – AI and ML

• 02: Anirban Maitra, MBBS, The University of Texas MD Anderson Cancer Center
• Andrew Hoofnagle, MD, PhD, University of Washington
• Sidney Fu, MD, National Cancer Institute

#3 Spatial-Omics

• 03: Cecilia Yeung, MD, Fred Hutchinson Cancer Center
• O. John Semmes, PhD, Eastern Virginia Medical School
• Indu Kohaar PhD, National Cancer Institute

#4 Cell Free DNA

• 04: Cristian Tomasetti, PhD, City of Hope/Tgen
• Joshua LaBaer, MD, PhD, Arizona State University
• Christos Patriotis PhD, National Cancer Institute

10:00 a.m. – 10:20 a.m.

Break

10:20 a.m. – 11:20 a.m.

Updates on EDRN Core Funded Projects

National Liver Cancer Screening Trial (TRACER) - Clinical Utility Trial for Hepatocellular Carcinoma

• 05: Amit Singal, MD, University of Texas Southwestern

Prostate MRI Biomarker Study (PMRI)

• 06: John T. Wei, MD, University of Michigan (virtual)

Pancreas CT Study

• 07: Anirban Maitra, MBBS, The University of Texas MD Anderson Cancer Center

11:20 a.m. – 11:30 a.m.

Final Remarks

• Karen Anderson, MD, PhD, Arizona State University
• Arul Chinnaiyan MD, University of Michigan

11:30 a.m.

Adjourn